ES2340842T3 - Anticuerpos anti-apc no neutralizantes. - Google Patents
Anticuerpos anti-apc no neutralizantes. Download PDFInfo
- Publication number
- ES2340842T3 ES2340842T3 ES03741459T ES03741459T ES2340842T3 ES 2340842 T3 ES2340842 T3 ES 2340842T3 ES 03741459 T ES03741459 T ES 03741459T ES 03741459 T ES03741459 T ES 03741459T ES 2340842 T3 ES2340842 T3 ES 2340842T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- nos
- activated protein
- neutralizing antibodies
- vivo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un anticuerpo contra la proteína C o la proteína C activada, que comprende regiones determinantes de la complementariedad que comprenden las secuencias de aminoácidos de: (a) SEQ ID NOs: 9, 10, 11 (VH), y SEQ ID NOs: 21, 22, 23 (VL), (b) SEQ ID NOs: 31, 32, 33 (VH), y SEQ ID NOs: 24, 25, 34 (VL), o (c) SEQ ID NOs: 15, 16, 17 (VH), y SEQ ID NOs: 27, 28, 29 (VL); en donde el anticuerpo comprende la actividad de (i) potenciar una actividad de la proteína C activada in vivo; (ii) suprimir la inactivación de la proteína C activada in vivo; o (iii) suprimir la inactivación de la proteína C activada, causada por (1) sangre; (2) un inhibidor fisiológico de la proteína C activada; o (3) tanto (1) como (2).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002212582 | 2002-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2340842T3 true ES2340842T3 (es) | 2010-06-10 |
Family
ID=30767813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03741459T Expired - Lifetime ES2340842T3 (es) | 2002-07-22 | 2003-07-17 | Anticuerpos anti-apc no neutralizantes. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7517965B2 (es) |
| EP (1) | EP1544214B1 (es) |
| JP (1) | JP4398369B2 (es) |
| AT (1) | ATE460431T1 (es) |
| AU (1) | AU2003281619A1 (es) |
| DE (1) | DE60331665D1 (es) |
| ES (1) | ES2340842T3 (es) |
| TW (1) | TW200407335A (es) |
| WO (1) | WO2004009641A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007101362A (ja) * | 2005-10-04 | 2007-04-19 | Hamamatsu Univ School Of Medicine | Ｅｉａプレート及びその利用方法 |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2429407T3 (es) | 2006-06-08 | 2013-11-14 | Chugai Seiyaku Kabushiki Kaisha | Agente preventivo o remedio para enfermedades inflamatorias |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| US8716218B2 (en) | 2007-11-06 | 2014-05-06 | Oklahoma Medical Research Foundation | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
| TW201634479A (zh) | 2007-12-05 | 2016-10-01 | 中外製藥股份有限公司 | 抗ｎｒ１０抗體及其應用 |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP2421900A1 (en) | 2009-04-24 | 2012-02-29 | Alper Biotech, Llc | Monoclonal antibodies against pcbp-1 antigens, and uses therefor |
| WO2012009577A2 (en) * | 2010-07-14 | 2012-01-19 | Alper Biotech, Llc | Monoclonal antibodies against pcbp-1 antigens, and uses therefor |
| MX2015006738A (es) * | 2012-11-29 | 2015-08-05 | Bayer Healthcare Llc | Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos. |
| TWI673063B (zh) * | 2013-09-20 | 2019-10-01 | 日商中外製藥股份有限公司 | 抗蛋白ｃ抗體之出血性疾病的治療 |
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| MX2022005654A (es) | 2019-11-20 | 2022-06-22 | Chugai Pharmaceutical Co Ltd | Preparacion que contiene anticuerpo. |
| CN118370814A (zh) * | 2023-01-20 | 2024-07-23 | 上海莱士血液制品股份有限公司 | 一种抗aPC单克隆抗体的制剂及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11A (es) * | 1836-08-10 | |||
| US1222929A (en) * | 1916-08-22 | 1917-04-17 | Brewster & Co | Brake mechanism for motor-cars. |
| US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| GB8327860D0 (en) | 1983-10-18 | 1983-11-16 | Fujisawa Pharmaceutical Co | Monoclonal antiprotein c antibody |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| EP0287028B1 (en) | 1987-04-17 | 1993-07-21 | Teijin Limited | Method of separating activated human protein c |
| CA2006684C (en) * | 1988-12-30 | 1996-12-17 | Charles T. Esmon | Monoclonal antibody against protein c |
| JP2749619B2 (ja) | 1989-03-10 | 1998-05-13 | エーザイ株式会社 | 活性化ヒトプロテインｃとヒトプロテインｃインヒビターの複合体の測定方法および測定試薬 |
| JPH03200066A (ja) | 1989-12-28 | 1991-09-02 | Tosoh Corp | 活性化ヒトプロテインｃの測定方法 |
| US5279956A (en) * | 1991-06-24 | 1994-01-18 | The Scripps Research Institute | Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C |
| WO1993009807A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels |
| DK0584348T3 (da) | 1992-03-11 | 2005-09-19 | Powderject Vaccines Inc | Genetisk vaccine mod immundefektvirusser |
| AU710106B2 (en) | 1994-06-10 | 1999-09-16 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein c |
| JPH1160500A (ja) * | 1997-08-11 | 1999-03-02 | Nippon Chem Res Kk | 血液凝固異常亢進抑制剤 |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| JPH11124399A (ja) | 1997-10-21 | 1999-05-11 | Eisai Co Ltd | プロテインｃインヒビターとプロテアーゼの複合体測定用モノクローナル抗体 |
| SE9900431D0 (sv) * | 1999-02-09 | 1999-02-09 | Johan Stenflo | Monoklonal antikropp |
| DE60236386D1 (de) | 2001-01-11 | 2010-07-01 | D Collen Res Foundation Vzw | Verfahren und pharmazeutische Zusammensetzung zur Vorbeugung und/oder Behandlung des Syndroms der systemischen entzündlichen Reaktion |
| EP1598368A4 (en) * | 2003-01-20 | 2007-07-25 | Chugai Pharmaceutical Co Ltd | ANTI-PCI neutralizing ANTIBODY |
-
2003
- 2003-07-16 TW TW092119361A patent/TW200407335A/zh not_active IP Right Cessation
- 2003-07-17 AU AU2003281619A patent/AU2003281619A1/en not_active Abandoned
- 2003-07-17 EP EP03741459A patent/EP1544214B1/en not_active Expired - Lifetime
- 2003-07-17 AT AT03741459T patent/ATE460431T1/de not_active IP Right Cessation
- 2003-07-17 WO PCT/JP2003/009087 patent/WO2004009641A1/ja not_active Ceased
- 2003-07-17 JP JP2004522748A patent/JP4398369B2/ja not_active Expired - Lifetime
- 2003-07-17 DE DE60331665T patent/DE60331665D1/de not_active Expired - Lifetime
- 2003-07-17 ES ES03741459T patent/ES2340842T3/es not_active Expired - Lifetime
- 2003-07-17 US US10/522,086 patent/US7517965B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE460431T1 (de) | 2010-03-15 |
| EP1544214B1 (en) | 2010-03-10 |
| TW200407335A (en) | 2004-05-16 |
| DE60331665D1 (de) | 2010-04-22 |
| JP4398369B2 (ja) | 2010-01-13 |
| EP1544214A4 (en) | 2007-03-28 |
| US7517965B2 (en) | 2009-04-14 |
| JPWO2004009641A1 (ja) | 2005-11-17 |
| WO2004009641A1 (ja) | 2004-01-29 |
| US20060121022A1 (en) | 2006-06-08 |
| EP1544214A1 (en) | 2005-06-22 |
| TWI322814B (es) | 2010-04-01 |
| AU2003281619A1 (en) | 2004-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2340842T3 (es) | Anticuerpos anti-apc no neutralizantes. | |
| NO2017027I1 (no) | efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
| CY1110322T1 (el) | Αναστολεις της her3 δραστικοτητας | |
| ECSP088962A (es) | Nuevos herbicidas | |
| EE200300408A (et) | Aktiivsete valkude saagise suurendamine | |
| CY1108689T1 (el) | Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα | |
| ATE517922T1 (de) | Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation | |
| CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
| CY1108765T1 (el) | ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2 | |
| IL145535A0 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
| CY1111193T1 (el) | Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους | |
| HUP0301877A2 (hu) | Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek | |
| AU2001272735A1 (en) | Novel physiologically active peptide and use thereof | |
| AU2002327308A1 (en) | Methods for evaluating pathologic conditions using extracellular rna | |
| ATE435657T1 (de) | Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung | |
| DE60223176D1 (de) | Metallkomplexverbindungen | |
| EA200501711A1 (ru) | Семейство секретируемых белков | |
| DE50308032D1 (de) | Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung | |
| EP1573055A4 (en) | GENETIC DEPRESSION DIAGNOSIS | |
| DK1569961T3 (da) | Splice variant af det menneskelige hypofysevæksthormon | |
| SE0202608D0 (sv) | New sequences | |
| AR056831A1 (es) | Metodo para el diagnostico y tratamiento de enfermedades cardiovasculares | |
| DE59911103D1 (de) | ISOLIERTE UND GEREINIGTE HUMANE LÖSLICHE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGC ALPHA1/BETA1) | |
| ATE343786T1 (de) | Auswertung von agenzien zur behandlung von schizophrenie | |
| EA200501843A1 (ru) | Tnf-подобный секретируемый белок |